Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 664 matching trials from the live ClinicalTrials.gov search.
Conditions
Delirium, Dementia
Interventions
Speed of Processing Training, Internet-Based Contact Control
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
65 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Phase 1 Interventional Results available

Cancer Vaccine Targeting Brachyury Protein in Tumors

NCT01519817
Conditions
Neoplasms, Malignant Solid Tumors, Colon Neoplasms, Adenocarcinoma
Interventions
GI-6301 (Yeast Brachyury Vaccine)
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Not applicable Interventional Accepts healthy volunteers

Deep Dive Randomized Control Trial

NCT00793260
Conditions
Chronic Disease, Arthritis, Uterine Diseases, Spinal Diseases, Preventive Health Services
Interventions
Enhanced Support, Usual-Support
Behavioral
Lead sponsor
Health Dialog
Industry
Eligibility
Not listed
Enrollment
174,120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Portland, Maine
Conditions
Multiple Sclerosis
Interventions
Balance targeted exercises
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Conditions
Renal Insufficiency, Chronic
Interventions
6R-BH4, 6R-BH4 placebo, Folic acid, Exercise training, Stretching, Histidine and beta-alanine supplementation, Histidine and beta-alanine placebo
Drug · Other · Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia
Conditions
Sarcoma
Interventions
sirolimus
Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
La Jolla, California • Boston, Massachusetts • New York, New York
Conditions
Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis, Run-in (short pre-surgery course) of endocrine-targeted therapy
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Inflammation, Perioperative Morbidity
Interventions
Dexamethasone Sodium Sulfate, Insulin, anesthesia management, Dexamethasone - placebo, Insulin - Placebo, Anesthesia management -Placebo
Drug · Other
Lead sponsor
d sessler
Other
Eligibility
40 Years to 90 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Kita-kyushu Lung Cancer Antigen 1, Human
Interventions
IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine, EKG, CXR, CT, MRI, PET, Biopsy, Acetaminophen, Ondansetron, Meperidine, Indomethacin, Famotidine
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Obsessive Compulsive Behavior
Interventions
Transcranial Magnetic Stimulation: continuous theta burst to pre supplementary motor area, Transcranial Magnetic Stimulation: Sham, Exposure with Response Prevention
Device · Behavioral
Lead sponsor
Bradley Hospital
Other
Eligibility
12 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Minneapolis, Minnesota • Providence, Rhode Island
Conditions
Major Depressive Disorder, Major Depressive Episode
Interventions
Universal Screening Arm
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Not listed
Enrollment
12,909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Leishmaniasis
Interventions
Miltefosine
Drug
Lead sponsor
Knight Therapeutics (USA) Inc
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Poolesville, Maryland
Completed Not applicable Interventional Accepts healthy volunteers Results available

Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project

NCT03326713
Conditions
Breast Cancer, Ovarian Cancer
Interventions
Telephone Counseling & Navigation (TCN), Mailed Targeted Print (TP), Usual Care (UC)
Behavioral · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years and older · Female only
Enrollment
668 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Completed Phase 2 Interventional Results available

CISPLATIN + AZD-1775 In Breast Cancer

NCT03012477
Conditions
Triple-negative Metastatic Breast Cancer
Interventions
Cisplatin, AZD1775
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Geographic Atrophy
Interventions
Sirolimus, Lidocaine
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
13
States / cities
Loma Linda, California • Sacramento, California • Jacksonville, Florida + 10 more
Conditions
Brain Tumors
Interventions
Induction therapy (Regimen 1, Course 1, Cycle A1, Regimen 1, Course 1, Cycle A2 (Days 22 - 42), Cycle B, Regimen 1, Course 2, Intrathecal Mafosfamide, Regimen 1 Course 2, IT mafosfamide, Regimen 2, Course 1, Regimen 2, Course, 1, Cycle C1, Regimen 2, Course 2, radiation therapy
Drug · Radiation
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 36 Months
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
3
States / cities
Durham, North Carolina • Memphis, Tennessee • Houston, Texas
Completed No phase listed Observational Results available

FREEZE-AFIB Post-Market Study

NCT05089877
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Surgical Ablation
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Hartford, Connecticut • New Haven, Connecticut • Evanston, Illinois + 3 more
Conditions
Lung Cancer
Interventions
Cisplatin, Amifostine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions
fluorine F 18 fluorothymidine, fludeoxyglucose F 18, positron emission tomography, diffusion-weighted magnetic resonance imaging, laboratory biomarker analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
7 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides
Interventions
Biodynamic imaging (BDI) of mycosis fungoides
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Completed Phase 1Phase 2 Interventional Results available

Cognitive Behavioral Therapy (CBT) for Tinnitus

NCT00724152
Conditions
Tinnitus
Interventions
Cognitive Behavioral Therapy, Tinnitus Education
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
Aggression, Self-injurious Behavior
Interventions
Trad FCT, Mult FCT, Mult FCT + Stimulus Fading
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
3 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Somerset, New Jersey
Completed Not applicable Interventional Accepts healthy volunteers

Real-world Evaluation of JBA GlucoTrojan With Reducose® on Glycemic Response

NCT06509204
Conditions
Food Habits
Interventions
Glucotrojan
Dietary Supplement
Lead sponsor
Tastermonial Inc
Industry
Eligibility
21 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cupertino, California
Conditions
Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
Interventions
ABM-168
Drug
Lead sponsor
ABM Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Francisco, California • Indianapolis, Indiana • New Brunswick, New Jersey + 3 more